ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Sunday, September 1, 2013

Submitted by

Source

Source Name: New England Journal of Medicine

Source URL: http://www.nejm.org/doi/full/10.1056/NEJMoa1300615?query=OF

Author(s)

John W. Eikelboom, Stuart J. Connolly, Martina Brueckmann, Christopher B. Granger, Arie P. Kappetein, Michael J. Mack, Jon Blatchford, Kevin Devenny, Jeffrey Friedman, Kelly Guiver, Ruth Harper, Yasser Khder, Maximilian T. Lobmeyer, Hugo Maas, Jens-Uwe Voigt, Maarten L. Simoons, and Frans Van de Werf, for the RE-ALIGN Investigators

This randomized trial of dabigatran vs warfarin for anticoagulation in patients immediately after or more than 3 mos after MVR or AVR with a mechanical valve was stopped early after enrollment of 252 pts. There were both excess bleeding events and excess thromboembolic events in the dabigatran group, indicating no benefit and increased risk of dabigatran compared to warfarin.